Search
Peter Molloy (left) and chairman William Garner founded Race Oncology in 2016 to commercialise Bisantrene. Photo: Attila Csaszar

Race challenges big pharma mindset

For many cancer sufferers, the side effects of traditional chemotherapy treatments can compound an already difficult situation.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Sign up for free emails

Complete your details below to receive our twice-daily news emails and our BN Weekender.

CAPTCHA
Thanks! This question prevents spammers...
Image CAPTCHA
Enter the characters shown in the image.

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/12/17

1 year TSR5 year TSR
thSpectur0%0%
104thRace Oncology132%0%
123rdSky and Space Global108%60%
805thProtean Energy-87%-40%
696 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

11/05/17
$17k Bought
30/03/17
$4k Bought
28/03/17
$20k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

219th-Protean Energy$0
220th↓Race Oncology$0
222nd-Sky and Space Global$0
223rd-Spectur$0
234 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer